Emails and information circulating on the 'net point to a rumor that the World Health
Organization (WHO) has released a pandemic virus into the population via a
"mock-up" vaccine. One story cites a WHO announcement (http://www.who.int/csr/disease/swin... Read the article at the end of
this one) which explains:
Also in Europe, some manufacturers have conducted advance studies using a so-called
"mock-up" vaccine. Mock-up vaccines contain an active ingredient for an
influenza virus that has not circulated recently in human populations and thus mimics the
novelty of a pandemic virus. Such advance studies can greatly expedite regulatory
approval.
The point of these "mock-up" vaccines is to allow vaccine manufacturers to gain
regulatory approvals for "placeholder" vaccines in advance of a pandemic. Once a
pandemic appears, the vaccine manufacturer can then replace the "mock-up" viral
strain in the vaccine with the newly emerging in-the-wild pandemic viral strain, thus
speeding the time to market for the new pandemic vaccine.
This process is explained in more detail in this EMEA (European Medicines Agency)
document:
http://www.emea.europa.eu/pdfs/gene...
It explains:
A mock-up pandemic influenza vaccine is a vaccine that mimics the future pandemic
influenza vaccine in terms of its composition and manufacturing method. However, because
the virus strain causing the pandemic is not known, the mock-up vaccine contains another
flu strain instead. This is a strain that is not circulating in humans, and to which
humans have not been exposed in the past. This enables the company to test its vaccine in
preparation for any flu pandemic that may occur in the future, by carrying out studies
with the mock-up vaccine that predict how people will react to the vaccine when the strain
causing a pandemic is included.
There are two things I find quite concerning in this statement:
#1) The viral strain chosen for this mock-up is one that is not currently circulating in
humans. Thus, they are choosing a viral strain to which humans have no acquired immune
defense.
#2) These mock-up vaccines are tested on humans in order to "predict how people will
react." Thus, the drug companies are engaged in injecting people with viral fragments
that have never been previously encountered by humans.
Obviously, if mistakes are made in the processing of these vaccines, causing live
viruses to be injected (instead of sufficiently weakened viruses), this could result in
the spread of that new virus among the human population. Thus, there is the possibility
that this process could be used as vector through which infectious disease is spread, but
it all depends on which virus is chosen for the mock-up vaccines.
And that's never explained in any public documents that I could find. Where do the drug
companies find these viruses to which humans have never been exposed? Are they getting
them from military labs? Animal experiments? Are they specifically chosen to be similar to
H1N1, or do they have a completely different protein configuration?
It is the selection of this viral strain that appears to be one of the most important
factors in all this.
In any case, it's clear that this mock-up process is pursued by vaccine manufacturers,
not the WHO itself, so I disagree with any report that states the WHO itself released a
pandemic virus into the population. The WHO is merely explaining what a mock-up
vaccine is. They aren't the ones manufacturing these mock-up vaccines or testing them on
humans. That's being done by the drug companies.
It also seems that calling the mock-up virus a "pandemic virus" may be
inaccurate. There's no way for us to know whether the mock-up virus is a pandemic virus or
just some harmless flu strain that poses no threat and isn't even contagious. Of course,
if the drug companies were maliciously trying to cause a pandemic, this is one way
they could potentially get it off the ground. And that's a distinct possibility, given all
the profit the drug companies are generating from the swine flu pandemic. But it's still
just conjecture at this point (unless there's some other documentation proof on this that
I don't know about, which is certainly possible).
The bottom line? These "mock-up" vaccines are a worrisome issue. It's clear that
swine flu vaccines are essentially experimental and that the People are being
treated like guinea pigs in all this. The motivation is clearly a Big Pharma profit
motive. But I'm not aware of any evidence suggesting that the World Health Organization
itself released a pandemic virus into the population via "mock-up" vaccines.
That notion may be an inadvertent misinterpretation of the publicly available documents.
The job of releasing a pandemic virus into the wild was likely accomplished by the drug
companies, if anyone. And they don't really need to use vaccines to release a new pandemic
into the population... All they need is to drive around Mexico City with one infected
person who sneezes on a few doorknobs.
What's really worrisome about all this, by the way, is that the mock-up vaccine process
allows drug companies to win pre-approval for a pandemic vaccine even before the
pandemic appears! Once the pandemic is under way, the drug manufacturer essentially pulls
a laboratory copy-and-paste maneuver to pop the pandemic virus into the vaccines,
replacing the mock-up virus. From there, it's an orgy of mass injections using this
completely untested new pandemic viral strain!
Essentially, the "mock-up vaccine" process allows drug companies to gain
approval for vaccines before they even exist.
How, exactly, is this good science? It isn't, of course. It's just more vaccine mongering
by Big Pharma combined with the utter abandonment of good science. Pandemic vaccines were
never about science in the first place, of course. They're all about making money and
scaring people into signing up for injections that will likely kill more people than they
save.
I'm glad people are raising awareness of the "mock-up" vaccine issue. It's a
topic that deserves closer inspection. It could even turn out to be one of the vectors
through which a pandemic is inadvertently (or intentionally) unleashed. (naturalnews,
9.04.2009, Mike Adams, the Health Ranger, NaturalNews Editor) http://www.naturalnews.com/026977_pandemic_vaccines_drug_companies.html
Additional sources:
Novartis mock-up vaccine:
http://www.bio-medicine.org/medicin...
Bacter's mock-up vaccine:
http://www.webwire.com/ViewPressRel...
WHO vaccine safety explanation: (Warning: contains pro-vaccine propaganda)
http://www.who.int/csr/disease/swin...
6 AUGUST 2009 | GENEVA -- WHO is aware of some media reports that have expressed concern about the safety of vaccines for pandemic influenza. The public needs to be reassured that regulatory procedures in place for the licensing of pandemic vaccines, including procedures for expediting regulatory approval, are rigorous and do not compromise safety or quality controls.
Vaccines are among the most important medical interventions for reducing illness and deaths during a pandemic. However, to have the greatest impact, pandemic vaccines need to be available quickly and in large quantities.
Pandemic
influenza vaccine manufacturing process and timeline |
During the 1957 and 1968 pandemics, vaccines arrived too late to be used as an effective mitigation tool during the more severe phases of the pandemics. Influenza vaccines had not yet been developed when the 1918 pandemic swept around the world, eventually killing an estimated 50 million people.
In 2007, as part of preparedness for an influenza pandemic, WHO worked together with health officials, regulatory authorities, and vaccine manufacturers to explore a broad range of issues surrounding the regulatory approval of pandemic vaccines. [1]
Ways were sought to shorten the time between the emergence of a pandemic virus and the availability of safe and effective vaccines. Different regulatory pathways were assessed, and precautions needed to ensure quality, safety, and effectiveness were set out in detail.
Regulatory authorities have shown great flexibility in developing procedures for fast-tracking the approval and licensing of pandemic vaccines.
In some cases, pandemic vaccines are not regarded by regulatory authorities as entirely “new” vaccines, as they build on the technology used to produce vaccines for seasonal influenza, established procedures for testing and regulatory control, and an extensive body of safety data.
In such cases, approval procedures are similar to those applied to “strain changes” made each year when seasonal vaccines are modified to match circulating viruses in the Northern and Southern Hemispheres.
Specific regulatory procedures have been devised to expedite the approval of pandemic vaccines. In the USA, for example, fewer data are required when the manufacturer already has a licensed influenza vaccine and intends to use the same manufacturing process for its pandemic vaccine.
In the European Union, the European Medicines Agency uses a rolling review procedure whereby manufacturers can submit sets of data for regulatory review as they become available, without having to wait until all data can be submitted together in a single formal application.
Also in Europe, some manufacturers have conducted advance studies using a so-called “mock-up” vaccine. Mock-up vaccines contain an active ingredient for an influenza virus that has not circulated recently in human populations and thus mimics the novelty of a pandemic virus. Such advance studies can greatly expedite regulatory approval.
Influenza vaccines have been used for more than 60 years and have an established record of safety in all age groups. While some serious adverse events have been reported, these have been rare.
Nonetheless, special safety issues will inevitably arise during a pandemic when vaccine is administered on a massive scale. For example, adverse events too rare to show up even in a large clinical trial may become apparent when very large numbers of people receive a pandemic vaccine.
Some adverse events will be coincidental – that is, associated in time with vaccine administration, yet not directly caused by the vaccine. Genuine adverse events directly caused by the vaccine may also occur, but cannot be predicted in advance. Given the safety record of seasonal vaccines, such events are expected to be rare.
Time constraints mean that clinical data at the time when pandemic vaccines are first administered will inevitably be limited. Further testing of safety and effectiveness will need to take place after administration of the vaccine has begun.
For these reasons, WHO advises all countries administering pandemic vaccines to conduct intensive monitoring for safety and efficacy, and many countries have plans in place for doing so. On the positive side, mass vaccination campaigns can generate significant safety data within a few weeks.
International sharing of data from such post-marketing surveillance will be vital in guiding risk-benefit assessments and determining whether changes in vaccination policies are needed. WHO has developed standardized protocols for data collection and reporting in real-time, and will communicate findings to the international community via its web site. http://www.who.int/csr/disease/swineflu/notes/h1n1_safety_vaccines_20090805/en/index.html